Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires

6. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders In Q3 2024: 81

Johnson & Johnson (NYSE:JNJ) is one of the biggest drug manufacturers and providers of general well-being products in the world. This means that despite facing claims from a multi-billion dollar talcum powder lawsuit, the firm can continue to focus on revenue growth and acquisitions. One such acquisition that’s made the news in 2025 is Johnson & Johnson (NYSE:JNJ)’s $14.6 billion bid for neuropsychiatric medicine provider Intra-Cellular. Cramer had quite a lot to say about the mega bid as he commented:

“This was an incredibly interesting $14.6 billion deal. Because Bristol Myers currently has Cobenfy, that’s just been approved, FDA, exactly for some of these indications that Intra-Cellular is supposed to be good for. Their drug has been [inaudible], this is Caplyta, since 2019, and has not curried the favor of psychiatrists so far. So I wanna find out how good this drug really is versus Cobenfy. You know and David the other thing I would say is, uh, finally, we are getting deals, and this is the kind of deal that I think actually might pass [inaudible] under the current FTC. But David, it is a sense, I think JNJ has had such a hard time. So many things have been going wrong, I will have Bristol Myers on later today. But JNJ just, is just, where, everywhere they turn, things are not working their way. Including a Boston Scientific competitor that was pulled from the market because of some neurological issues involving four different people last week. So, you know, I’m gonna stay in touch with this area David, but JNJ’s been luckless. Maybe this can change their streak. But I want to hear what Bristol says, because Bristol’s got the one that everybody is buzzing about. Which is Cobenfy. Not what Intra-Cellular has.”